TFFP TFF Pharmaceuticals Inc - Ordinary Shares

Biotech Analyst Ratings

Latest News

1. 11 May 2022 TFF Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update

   Announced Collaboration with Catalent to Further Expand Thin Film Freezing Applications with a Focus on Biologic Drug Development
   

   Announced Second CRADA Agreement with USAMRIID and Geneva Foundation to Develop Novel Therapies Using Thin Film Freezing to Combat SARS-CoV-2, Ebola, and Marburg Viruses

   Initiated Phase 2 Trials of Inhaled Voriconazole Powder and Inhaled Tacrolimus Powder With Interim Data for Each Program Expected Later in 2022

   Significant Progress Made in Inhaled Niclosamide Powder Program

   Multiple Abstracts Highlighting Applications of Thin Film Freezing Presented at Respiratory Drug Delivery (RDD) Meeting

   Conference Call and Webcast Scheduled Today, Wednesday, May 11, 2022 at 4:30 PM ET

   FORT WORTH, Texas, May 11, 2022…

   View Full Article
2. 02 May 2022 TFF Pharmaceuticals Announces Multiple Presentations Highlighting Broad Applicability of its Thin Film Freezing Technology at Respiratory Drug Delivery Meeting (RDD)

   …

   View Full Article
3. 29 April 2022 TFF Pharmaceuticals to Hold First Quarter 2022 Financial and Business Results Conference Call on May 11, 2022

   FORT WORTH, Texas, April 29, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that it will release its financial results and business update for the first quarter of 2022 on Wednesday, May 11, 2022, after the close of the U.S. financial markets.
   

   Conference Call and Webcast Information

   The Company will host a conference call on Wednesday, May 11, 2022, at 4:30 PM ET to review the clinical, corporate and financial highlights. A question-and-answer session with investors will follow management's remarks. To participate in the conference…

   View Full Article
4. 19 April 2022 TFF Pharmaceuticals Announces Safety and Pharmacokinetic Data from Phase 1 Study of Niclosamide Inhalation Powder

   Niclosamide Inhalation Powder Well Tolerated with No Serious Adverse Events Across All Subject Cohorts
   

   Current Data Suggests Niclosamide Inhalation Powder is a Promising Antiviral Treatment to Combat COVID-19

   FORT WORTH, Texas, April 19, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced safety and pharmacokinetic (PK) data from its Phase 1 study of Niclosamide Inhalation Powder, which is being developed for the treatment of COVID-19.

   "We are very pleased to announce these positive safety and PK data for our Niclosamide Inhalation…

   View Full Article
5. 24 March 2022 TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

   Pipeline Advancement Continues with Ongoing Phase 2 Studies for Voriconazole and Tacrolimus Programs
   

   Partnership Activity Surrounding Thin Film Freezing Continues to Expand Reflecting the Technology's Broad Applicability Across Molecule Type and Therapeutic Area

   Appoints Life Sciences Executive, Brandi Roberts, to Board of Directors and Anthony Hickey, Ph.D. as Chief Scientific Officer

   Expands Leadership Team With Senior Appointments in Product Development and Manufacturing, Government and Strategic Initiatives, and Regulatory Affairs

   Conference Call and Webcast Scheduled Today, Thursday, March 24, 2022, at 4:30 PM ET

   FORT WORTH, Texas, March 24, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP), a clinical-stage biopharmaceutical…

   View Full Article